Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Tirelizumab + gemcitabine/cisplatin for unresectable recurrent nasopharyngeal carcinoma (first-line)
ChiCTR2400084390Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: 1-year local/regional recurrence-free survival rate and progression-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400084390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084390.